Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg

(Length of Discussion: 10 min)

Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion wiht Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2nd line therapy.  A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radium-223 dichloride in bone metastatic castration-resistant prostate cancer (mCRPC).   Finally, they review the health-related quality of life (HRQoL) survey following the PROSPER study, a presentation by Gerhardt Attard, MD, and colleagues who presented deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (nmCRPC or M0).  

Related Content:
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer

Results from the PROSPER Study: HRQoL Deterioration and Pain Progression in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Biographies:

Cora Sternberg MD, FACP is chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy. She has attained the rank of full Professor of Oncology and is an adjunct professor at La Sapienza University in Rome. She is also adjunct professor of Urology and Urological Oncology at Tufts University School of Medicine and the Lahey Clinic in Boston, Massachusetts, and adjunct professor at Temple University’s College of Science and Technology in Philadelphia, Pennsylvania. A graduate of the University of Pennsylvania undergraduate and medical schools, she completed her fellowship and was on staff at Memorial Sloan Kettering Cancer in NY. Dr. Sternberg is an internationally respected leader in the fields of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is the principal investigator for numerous studies and an internationally respected researcher who has lectured extensively at universities and cancer symposia worldwide. Dr. Sternberg is particularly known for her influential work in bladder cancer and for her publications on novel therapies for prostate cancer and targeted agents in renal cell carcinoma. Dr. Sternberg has published extensively (more than 375 articles, 6 textbooks) and is an associate editor and editorial board member of several International journals. European School of Oncology (ESO) core faculty and in tune with American medicine, Dr. Sternberg has been elected for a 3-year term to the nominating committee of ASCO’s board of directors.

Alicia Morgans, MD.